WO2010061142A3 - Composition comprenant un antagoniste du recepteur at2 de l ' angiotens ine ii pour retarder l ' initiation tumorale de cellules cancereuses chez un mammifere a risque - Google Patents

Composition comprenant un antagoniste du recepteur at2 de l ' angiotens ine ii pour retarder l ' initiation tumorale de cellules cancereuses chez un mammifere a risque Download PDF

Info

Publication number
WO2010061142A3
WO2010061142A3 PCT/FR2009/052311 FR2009052311W WO2010061142A3 WO 2010061142 A3 WO2010061142 A3 WO 2010061142A3 FR 2009052311 W FR2009052311 W FR 2009052311W WO 2010061142 A3 WO2010061142 A3 WO 2010061142A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
composition containing
receptor antagonist
intended
cancer cell
Prior art date
Application number
PCT/FR2009/052311
Other languages
English (en)
Other versions
WO2010061142A2 (fr
Inventor
Sébastien FAURE
Daniel Henrion
Nicolas Clere
Original Assignee
Universite D'angers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite D'angers filed Critical Universite D'angers
Publication of WO2010061142A2 publication Critical patent/WO2010061142A2/fr
Publication of WO2010061142A3 publication Critical patent/WO2010061142A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition préventive antitumorale comprenant une quantité pharmaceutiquement efficace d'au moins un antagoniste du récepteur AT2 de l'angiotensine II pour son application comme médicament afin de prévenir le développement de cancers chez un mammifère à risque. La présente invention concerne également un procédé de prévention du développement de cancer chez un mammifère à risque, ainsi qu'un kit de prévention du développement de cancers.
PCT/FR2009/052311 2008-11-28 2009-11-26 Composition pour retarder l'initiation tumorale de cellules cancéreuses chez un mammifère a risque WO2010061142A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0806715 2008-11-28
FR0806715A FR2939043B1 (fr) 2008-11-28 2008-11-28 Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque

Publications (2)

Publication Number Publication Date
WO2010061142A2 WO2010061142A2 (fr) 2010-06-03
WO2010061142A3 true WO2010061142A3 (fr) 2010-08-12

Family

ID=40404073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/052311 WO2010061142A2 (fr) 2008-11-28 2009-11-26 Composition pour retarder l'initiation tumorale de cellules cancéreuses chez un mammifère a risque

Country Status (2)

Country Link
FR (1) FR2939043B1 (fr)
WO (1) WO2010061142A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005784A1 (fr) * 1990-10-02 1992-04-16 Warner-Lambert Company Derives et analogues de 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine utilises comme antagonistes des recepteurs de l'angiotensine ii
WO2002087503A2 (fr) * 2001-04-26 2002-11-07 Vanderbilt University Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
EP1444988A1 (fr) * 2001-11-13 2004-08-11 Takeda Chemical Industries, Ltd. Agents anticancer
WO2008060899A2 (fr) * 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Procédés de dépistage et de traitement du cancer du sein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005784A1 (fr) * 1990-10-02 1992-04-16 Warner-Lambert Company Derives et analogues de 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine utilises comme antagonistes des recepteurs de l'angiotensine ii
WO2002087503A2 (fr) * 2001-04-26 2002-11-07 Vanderbilt University Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
EP1444988A1 (fr) * 2001-11-13 2004-08-11 Takeda Chemical Industries, Ltd. Agents anticancer
WO2008060899A2 (fr) * 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Procédés de dépistage et de traitement du cancer du sein

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AGER E I ET AL: "The renin-angiotensin system and malignancy", CARCINOGENESIS 2008 GB, vol. 29, no. 9, July 2008 (2008-07-01), pages 1675 - 1684, XP002532473 *
CHUA C C HAMDY R C CHUA B H: "Regulation of thrombospondin-1 production by angiotensin II in rat heart endothelial cells", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD- DOI:10.1016/S0167-4889(97)00029-3, vol. 1357, no. 2, 27 June 1997 (1997-06-27), pages 209 - 214, XP004277618, ISSN: 0167-4889, [retrieved on 19970801] *
KANEHIRA TSUTOMU ET AL: "Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-beta-dependent cell growth attenuation.", CANCER RESEARCH 1 SEP 2005, vol. 65, no. 17, 1 September 2005 (2005-09-01), pages 7660 - 7665, XP002532472, ISSN: 0008-5472 *
KITAYAMA H ET AL: "Regulation of Angiogenic Factors in Angiotensin II Infusion Model in Association With Tubulointerstitial Injuries", AMERICAN JOURNAL OF HYPERTENSION, ELSEVIER LNKD- DOI:10.1016/J.AMJHYPER.2005.09.022, vol. 19, no. 7, 1 July 2006 (2006-07-01), pages 718 - 727, XP024903865, ISSN: 0895-7061, [retrieved on 20060701] *
RIZKALLA BISHOY ET AL: "Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system", JOURNAL OF HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, LTD, US / UK, vol. 23, no. 1, 1 January 2005 (2005-01-01), pages 153 - 164, XP008122909, ISSN: 0263-6352 *
SARLOS STELLA ET AL: "Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin.", AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 3, September 2003 (2003-09-01), pages 879 - 887, XP002585681, ISSN: 0002-9440 *
TAKAGI T ET AL: "Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis", CARCINOGENESIS 2002 GB, vol. 23, no. 7, 2002, pages 1235 - 1241, XP002532471, ISSN: 0143-3334 *
XU YI ET AL: "AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 282, no. 4 Part 2, April 2002 (2002-04-01), pages H1206 - H1215, XP008122929, ISSN: 0002-9513 *

Also Published As

Publication number Publication date
FR2939043A1 (fr) 2010-06-04
FR2939043B1 (fr) 2011-03-04
WO2010061142A2 (fr) 2010-06-03

Similar Documents

Publication Publication Date Title
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
IL243376A0 (en) Antagonistic antibody against epha2 for cancer treatment
WO2010056754A3 (fr) Inhibition de cible mammalienne de rapamycine
WO2008112199A8 (fr) Procédé d'inhibition de la topoisomérase ii
WO2009091898A3 (fr) Composés de 6-aminoisoquinoléine et 7-aminoisoquinoléine et leurs procédés de fabrication et d'utilisation
EP1991701A4 (fr) Compositions, kits, et procédés pour identifier, évaluer, prévenir et traiter un cancer
WO2012078633A3 (fr) Méthodes d'inhibition de la métastase d'un cancer
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
MY175800A (en) Combination treatment of cancer
WO2008115262A3 (fr) Inhibiteurs de hsp90 contenant une fraction de liaison de zinc
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2010062377A3 (fr) Procédés et compositions pour la détection et le traitement de l’éclampsie
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
IL180350A0 (en) Compositions for delivering highly water soluble drugs
WO2010141842A3 (fr) Procédé combiné de traitement d'un cancer ou d'un état précancéreux
WO2009002808A3 (fr) Composés de quinazolinone et leurs méthodes d'utilisation
WO2005037205A3 (fr) Composes substitues par haloacetamide et azide, et methodes d'utilisation des composes
MX341174B (es) Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
AP2010005231A0 (en) Anti-malarial pharmaceutical composition
EA201001312A1 (ru) Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик
WO2009105217A3 (fr) Inhibiteurs du complément en tant qu'agents thérapeutiques pour le traitement du cancer
MX341450B (es) Composicion farmaceutica antihipertensiva.
EP2277840A4 (fr) Accélérateur de durcissement pour composition hydraulique
WO2010051320A3 (fr) Procédés pour assembler des plaques de lignées cellulaires cancéreuses utilisées pour tester une ou plusieurs compositions pharmaceutiques
WO2009114470A3 (fr) Tétrahydroindole et tétrahydroindazole utilisés comme inhibiteurs de hsp90, contenant un fragment de liaison à du zinc

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09797099

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09797099

Country of ref document: EP

Kind code of ref document: A2